This website uses functional cookies, including analytical cookies.
The obtained statistical data cannot be traced back to individual users.
Additionally, you can choose to accept or refuse consent to use marketing cookies.
If you decline these additional cookies or refrain from making a choice, only functional cookies will be set.
See our cookie policy for more information.
Xencor Inc has appointed RSM MSCBA alumnus Bart Cornelissen as chief financial officer to support its clinical-stage pipeline of engineered antibodies for the treatment of cancer and other serious diseases.